View Older Stories View More Recent Stories

Jun 1, 2023 07:30AM Arrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi Therapeutics
May 23, 2023 07:31AM Arrowhead Pharmaceuticals (ARWR) Presents Interim Data from ARO-ANG3 Phase 2 GATEWAY Study
May 23, 2023 07:30AM Arrowhead Presents Interim Data from ARO-ANG3 Phase 2 GATEWAY Study in Patients with HoFH
May 16, 2023 07:30AM Arrowhead Pharmaceuticals Completes Enrollment of Phase 3 PALISADE Clinical Trial Evaluating ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
May 15, 2023 04:00PM Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
May 2, 2023 04:01PM Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results
Apr 25, 2023 07:32AM Arrowhead Pharmaceuticals (ARWR) Announces TRiM Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect
Apr 25, 2023 07:30AM Arrowhead Pharmaceuticals’ Proprietary Pulmonary TRiM™ Platform Achieves High Levels of Target Gene Knockdown and Long Duration of Effect
Apr 18, 2023 07:30AM Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Second Quarter Results
Apr 12, 2023 07:30AM Arrowhead Pharmaceuticals (ARWR) to Host R&D Day on Pipeline of RNAi Therapeutics
Apr 12, 2023 07:30AM Arrowhead Pharmaceuticals to Host R&D Day on Pipeline of RNAi Therapeutics
Apr 4, 2023 07:30AM First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead
Apr 3, 2023 07:30AM Arrowhead Pharmaceuticals (ARWR) Announces $30 Million Milestone Payment from GSK
Apr 3, 2023 07:30AM Arrowhead Pharmaceuticals Announces $30 Million Milestone Payment from GSK
Mar 31, 2023 04:30PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Mar 20, 2023 07:30AM Arrowhead Pharmaceuticals Inc. (ARWR) Receives FDA Fast Track Designation for ARO-APOC3
Mar 20, 2023 07:30AM Arrowhead Receives FDA Fast Track Designation for ARO-APOC3
Mar 3, 2023 07:30AM Arrowhead Pharmaceuticals to Present at 43rd Annual Cowen Health Care Conference
Feb 28, 2023 07:30AM Arrowhead Pharmaceuticals Inc. (ARWR) Reports Interim Results from Ongoing Phase 1/2 Study of ARO-C3
Feb 28, 2023 07:30AM Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases
Feb 15, 2023 07:30AM Arrowhead Pharmaceuticals Inc. (ARWR) Gains Full Rights to NASH Candidate ARO-PNPLA3
Feb 15, 2023 07:30AM Arrowhead Pharmaceuticals Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results
Feb 6, 2023 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2023 First Quarter Results
Feb 2, 2023 07:30AM Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis
Jan 25, 2023 07:30AM Arrowhead Pharmaceuticals to Webcast Fiscal 2023 First Quarter Results
Jan 9, 2023 07:30AM Takeda (TAK) and Arrowhead (ARWR) Report Topline Results from SEQUOIA Phase 2 Study of Fazirsiran
Jan 9, 2023 07:30AM Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Dec 21, 2022 04:00PM Arrowhead Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference
Dec 21, 2022 07:30AM Arrowhead Pharmaceuticals to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study
Dec 20, 2022 07:30AM Arrowhead (ARWR) Receives $25M Milestone Payment from Amgen (AMGN)
Dec 20, 2022 07:30AM Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen
Dec 15, 2022 04:30PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Dec 8, 2022 08:04AM Arrowhead Pharmaceuticals (ARWR), Horizon Therapeutics (HZNP) enrolls first patient in HZN-457 phase 1 trial for gout
Dec 8, 2022 08:00AM Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
Dec 8, 2022 08:00AM Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
Nov 28, 2022 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2022 Year End Results
Nov 21, 2022 04:00PM Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
Nov 14, 2022 04:30PM Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Year End Results
Nov 9, 2022 08:11AM Arrowhead Pharmaceuticals (ARWR) Sells Royalty Interest in Olpasiran to Royalty Pharma (RPRX) for $250 Million and Future Milestones
Nov 9, 2022 08:10AM Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
Nov 7, 2022 04:09PM Arrowhead Pharmaceuticals (ARWR) Presents New Phase 2 Data
Nov 7, 2022 04:08PM Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline
Oct 13, 2022 04:30PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Oct 11, 2022 07:30AM Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3
Sep 1, 2022 07:30AM Arrowhead Pharmaceuticals to Participate in Upcoming September 2022 Conferences
Aug 17, 2022 07:33AM Arrowhead Pharmaceuticals Inc. (ARWR) Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis
Aug 17, 2022 07:30AM Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis
Aug 4, 2022 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results
Jul 20, 2022 04:00PM Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Third Quarter Results
Jul 8, 2022 04:30PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
View More Recent Stories View Older Stories